Efficacy and Safety of Benralizumab in Patients with Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study) - HUDSON GI

Study identifier:D3258C00001

ClinicalTrials.gov identifier:NCT05251909

EudraCT identifier:2021-000085-14

CTIS identifier:N/A

Study Complete

Official Title

A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled 3-Part Phase 3 Study to Demonstrate the Efficacy and Safety of Benralizumab in Patients with Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study)

Medical condition

Eosinophilic gastritis

Phase

Phase 3

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

12

Study type

Interventional

Age

12 Years - 130 Years

Date

Study Start Date: 18 Jan 2022
Primary Completion Date: 13 Feb 2024
Study Completion Date: 13 Feb 2024

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Feb 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria